Figure 1From: Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind studySummary of study schematic from screening through study completion. Visits 6, 7, and 8 were conducted at 4-week intervals. Adverse events were collected from Weeks 1 to 25. Sleep variables were obtained at Week −1 (baseline) and Weeks 1 to 4. SF-36 was assessed at Weeks −1, 4, 12 and 24.Back to article page